Title:
HETEROCYCLIC COMPOUND FOR INHIBITING AND/OR INDUCING DEGRADATION OF KRAS PROTEIN
Document Type and Number:
WIPO Patent Application WO/2024/034591
Kind Code:
A1
Abstract:
To provide a compound useful as an active ingredient of a pharmaceutical composition for treating cancer, in particular, pancreatic cancer. The present inventors examined compounds useful as an active ingredient of a pharmaceutical composition for treating cancer, in particular, pancreatic cancer, and discovered that a heterocyclic compound represented by formula (I) has an excellent action for inducing the degradation of KRAS protein and/or a KRAS inhibitory activity and can be used as a therapeutic agent for cancer, in particular, pancreatic cancer, thereby completing the present invention. This heterocyclic compound or a salt thereof can be used as a therapeutic agent for cancer, in particular, pancreatic cancer.
Inventors:
YOSHINARI TOMOHIRO (JP)
ISHIOKA HIROKI (JP)
TAKAHASHI FUMIE (JP)
KAMIKUBO TAKASHI (JP)
KAWAMINAMI EIJI (JP)
KURAMOTO KAZUYUKI (JP)
NAGASHIMA TAKEYUKI (JP)
INAMURA KOHEI (JP)
ISHIOKA HIROKI (JP)
TAKAHASHI FUMIE (JP)
KAMIKUBO TAKASHI (JP)
KAWAMINAMI EIJI (JP)
KURAMOTO KAZUYUKI (JP)
NAGASHIMA TAKEYUKI (JP)
INAMURA KOHEI (JP)
Application Number:
PCT/JP2023/028860
Publication Date:
February 15, 2024
Filing Date:
August 08, 2023
Export Citation:
Assignee:
ASTELLAS PHARMA INC (JP)
International Classes:
C07D401/14; A61K31/496; A61K31/517; A61K31/519; A61K31/551; A61P1/18; A61P35/00; A61P43/00; C07D403/14; C07D487/08; C07D519/00
Domestic Patent References:
| WO2022078414A1 | 2022-04-21 | |||
| WO2022078470A1 | 2022-04-21 | |||
| WO2022105855A1 | 2022-05-27 | |||
| WO2022002102A1 | 2022-01-06 | |||
| WO2017172979A1 | 2017-10-05 | |||
| WO2022173032A1 | 2022-08-18 | |||
| WO2023280026A1 | 2023-01-12 |
Attorney, Agent or Firm:
YAMAMOTO, Osamu et al. (JP)
Download PDF: